证券代码：688016 证券简称：心脉医疗 公告编号：2026-004 上海微创心脉医疗科技（集团）股份有限公司 2025年年度业绩快报公告 报告期内，公司实现营业总收入135,063.27万元，同比增长11.96%；实现营业利润65,389.17万元，同比 下降1.10%；实现利润总额65,337.47万元，同比增长0.18%；归属于母公司所有者的净利润56,321.31万 元，同比增长12.17%；归属于母公司所有者的扣除非经常性损益的净利润50,216.70万元，同比增长 26.97%；基本每股收益4.65元，同比增长14.25%。报告期末，公司总资产464,046.77万元，较年初增长 8.13%；归属于母公司的所有者权益407,565.93万元，较年初增长7.48%；归属于母公司所有者的每股净 资产33.63元，较年初增长9.03%。 2、影响经营业绩的主要因素 报告期内，公司创新产品在巩固国产领先优势的基础上，通过下沉市场、提供定制化治疗方案以及产品 升级迭代，加速推广新品、替换老产品等策略，推动市占率稳步提升，但考虑到2024年市场价格治理因 素影响的延续性，公司部分产品价格及推广策略的调整因素 ...

Core Viewpoint - MicroPort Medical (00853) reported a revenue of approximately 1.351 billion yuan for HeartPulse Medical (688016.SH) in 2025, marking a year-on-year increase of 11.96%, with a net profit attributable to the parent company of about 563 million yuan, up 12.17% year-on-year, and basic earnings per share of 4.65 yuan [1] Group 1: Financial Performance - The total revenue for the reporting period was approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - The net profit attributable to the parent company was around 563 million yuan, showing a year-on-year increase of 12.17% [1] - Basic earnings per share were reported at 4.65 yuan [1] Group 2: Product Development and Market Strategy - The company has accelerated the promotion of new products and replacement of old products through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - The company launched multiple innovative products in the domestic market, including the Cratos branched aortic stent graft system and other medical devices, with a total of 23 products receiving NMPA registration and 11 products obtaining registration in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products like the Aegis II abdominal aortic stent graft system and Hector thoracic multi-branch stent graft system progressing through various stages of clinical trials and regulatory submissions [3] Group 3: International Sales and Market Expansion - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of the company's total revenue [1] - The company is actively pursuing collaborations with leading regional clients globally and advancing the market access and promotion of aortic and peripheral interventional products in Europe, Latin America, and Asia-Pacific [1] - The company’s products are now sold in 49 countries and regions, including China [1]

公司新增多款创新产品在国内获批上市，包括 Cratos 分支型主动脉覆膜支架系统、经颈静脉肝内穿刺 套件、聚乙烯醇栓塞微球。公司累计 23 款产品获得 NMPA 首次注册证，11 款产品在 28 个海外市场获 得首次注册证;累计获得海外产品注册证 110 余张，其中 6 款产品获得 CE 认证，3 款产品获得欧盟定制 证书。 除上述产品外，公司在研产品稳步推进，管线丰富，其中 Aegis II 腹主动脉覆膜支架系统完成注册资料 递交;Hector 胸主多分支覆膜支架系统已进入国内上市前多中心临床阶段，且于报告期内进入国家创 新"绿色通道"，并已通过欧盟定制方式实现商业化，同时该产品美国 Breakthrough Device Designation 申请已提交 FDA;胸腹主动脉覆膜支架系统(定制)已获得国内备案证;髂动脉分支覆膜支架系统即将进入 临床试验启动阶段。外周业务方面，外周介入微导管、可解脱带纤维毛栓塞弹簧圈、机械血栓切除导 管、新一代外周裸球囊导管预计 2026 年获批上市;膝下药物球囊扩张导管、TIPS 覆膜支架系统已完成 注册递交;外周血管药物洗脱支架系统处于临床植入阶段。同时，公司创新产品的 ...